Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Track down Your Optimal Conservative Vehicle: Famous Brands to Consider - 2The Best Competitors of the 21st Hundred years
- 3Make your choice for a definitive Christmas getaway destination!
- 4Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
- 5Examination In progress into Abuse of Japanese Government-Supported Advance
- She just became the first wheelchair user to travel to space
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- 6 Exceptionally Appraised Summer Travel Objections
- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Journey Travel Objections for Your Next Experience
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- 10 Demonstrated Systems to Develop Your Internet based Business
